GU Cancers 2024 | Choosing the correct PARP inhibitor for prostate cancer

Kim Chi, MD, BC Cancer Vancouver Centre, Vancouver, Canada, discusses remaining questions surrounding the use of PARP inhibitors for the management of prostate cancer. Comparing different PARP inhibitors can be difficult due to different trial designs and selection criteria. Additional research will be needed to compare sequential therapy with combination therapy. The former can consist of androgen receptor pathway inhibition (ARPI) followed by PARP inhibitors, whereas the latter can combine abiraterone or enzalutamide with niraparib, olaparib, or talazoparib. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.